Global Newsroom

KING OF PRUSSIA, PA and MELBOURNE, AU

• CSL advances novel pipeline spanning six therapeutic areas, four scientific platforms and two businesses (CSL Behring and Seqirus)
• Seqirus Awarded BARDA contract to develop aQIVc and sa-mRNA Pandemic Influenza Vaccines
• New collaboration with the Walter and Eliza Hall Institute for Medical Research in Australia to create a Centre for Biologic Therapies

Kankakee, IL

CSL introduced a scholarship program for U.S. employees and their dependents as part of delivering on its promise to diversity, equity and inclusion.

Here's how CSL is working around the world with academia, industry and governments to combat COVID-19

KING OF PRUSSIA, Pa. and PHILADELPHIA, Pa.

Global biotech leader CSL and the Urban League of Philadelphia are working to address some of the most pressing needs in the community, including efforts to strengthen Public Health, Leadership Development, Workforce Diversity and Job Creation and Training.

King of Prussia, Pa.

The updated guideline empowers physicians with the confidence to expand the treatment options prescribed for CIDP patients

KING OF PRUSSIA, PA

Approval received to co-package a convenience administration kit along with the product BERINERT.

KING OF PRUSSIA, Pa.

Hizentra will be covered under the same Medicare benefit category as intravenous immune globulin (IVIg), but with the convenience of self-infusing at home

CSL continues to provide medicines to patients around the world.

KING OF PRUSSIA, Pa.

Findings signal need for novel treatment strategies to provide more protection during this high-risk, 90-day period

NEW YORK, NY, USA

Dr. Minnie Sarwal of NephroSant has been selected to receive the $25,000 Innovation Award

KING OF PRUSSIA, PA

• Etranacogene dezaparvovec (AMT-061) is an investigational gene therapy that may potentially provide people with hemophilia B with years of functional levels of Factor IX, a blood-clotting protein that prevents excessive bleeding.

• uniQure will complete the Phase 3 HOPE-B trial and scale up manufacture for initial commercial supply under an agreed plan with CSL Behring.

King of Prussia, Pa

The label update is based on open label extension data from the landmark PATH (Polyneuropathy And Treatment with Hizentra) study

Osaka, JAPAN and King of Prussia, Pa., USA

Phase 3 Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC) clinical trial sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), did not meet its endpoints to show efficacy in adults hospitalized with COVID-19

NEW YORK

• TransplantLyfe is an online community for those living with an organ transplant, their support partners and donors to share experiences, find one-on-one mentorships and help individuals feel safe as they embrace struggles unique to transplantation, regardless of their physical location.

• TransplantLyfe addresses a major unmet need for those living with organ transplantation: most notably, the support and communication gap between individuals with similar experiences in the transplant journey.

KING OF PRUSSIA, Pa.

- Reduction in number of attacks is leading factor when evaluating prophylactic therapy

KING OF PRUSSIA, Pa. and PHILADELPHIA, Pa.

- 6 Urban League Affiliates across U.S. to participate -- starting with Philadelphia

KING OF PRUSSIA, Pa.

Global biotherapeutics leader reinforces commitment to cardiovascular research: Hosts Learning Studio with prominent cardiovascular thought leaders to discuss emerging treatment targets

KING OF PRUSSIA, Pa.

The AEGIS-II trial is evaluating the efficacy and safety of CSL112 (apolipoprotein A-1 [human]) during the high-risk 90-day period following a heart attack

KING OF PRUSSIA, Pa.

• Both US and European regulators grant special designation
• Phase 1 clinical development underway for CSL889

KING OF PRUSSIA, Pa.

- Forbes Recognizes Global Biotechnology Leader for Fourth Straight Year